Week of Feb. 13, 2012: Alexion Completes Acquisition of Enobia Pharma; BMS Completes Acquisition of Inhibitex; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Feb. 13, 2012: Alexion Completes Acquisition of Enobia Pharma; BMS Completes Acquisition of Inhibitex; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

The biopharmaceutical company Alexion Pharmaceuticals has completed its $1.1-billion acquisition of 100% of the capital stock of Enobia Pharma, a biopharmaceutical company focused on the development of therapies for treating genetic metabolic disorders. Goldman, Sachs & Co. acted as financial advisor to Alexion. Ropes and Gray LLP acted as lead legal counsel to Alexion, and Cassels Brock & Blackwell LLP acted as Canadian legal counsel to Alexion. Read More

The CDMO Almac has announced that it is doubling its analytical capacity at its 240,000-ft2 North American headquarters in Souderton, Pennsylvania. The facility offers full-service, integrated clinical packaging, drug-supply management, and technology services to pharmaceutical and biotechnology clients. Almac’s additional laboratory investment will include polymorph and salt screening, and solid-form development. The new facility is also equipped with a bathless dissolution apparatus for comparative dissolution studies. Read More

Bosch Packaging Technology has announced plans to acquire the machinery business companies of Eisai. Respective agreements were signed on Feb. 8, 2012. Eisai's machinery business specializes in inspection machinery for the pharmaceutical industry. Bosch Packaging Technology and Eisai have agreed to keep the purchase price confidential. The transaction is subject to compliance with antitrust legislation. Read More

Bristol-Myers Squibb has completed its $2.5-billion acquisition of the clinical-stage biotechnology company Inhibitex. The deal was valued at a purchase price of $26.00 per share. As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. As of the close of business on Feb. 10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery procedures. Read More

Takeda Pharmaceutical has announced the establishment of the Takeda Shanghai Development Center (TDSC) within the Shanghai-based Takeda (China) Holdings (TCH), which is a wholly owned subsidiary of Takeda. TDSC will expand the company’s clinical-development activities within the Asian region, with a focus on China for general medicine. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here